Novacyt (ALNOV)
Euronext Paris · France · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 0.453 |
|---|---|
| 52-week range | 0.290 – 1.040 |
| Return, 1 month / 3 months | −10.7% / +0.7% |
| Return, 1 year / 3 years | −6.2% / −5.6% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 42 |
| Volatility (1 year) | 93.7% |
| Worst drawdown (1 year) | -57.3% |
| Average daily value traded | 0.14M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Novacyt is a diagnostics company based in France that develops and supplies molecular testing products. It makes laboratory instruments and reagent kits used to detect infectious diseases and other conditions, serving hospitals, clinical laboratories and healthcare providers. Its work centres on polymerase chain reaction technology and related diagnostic systems, and it also offers testing services through its laboratory operations. The company sells its products to customers in healthcare and research settings across several countries.
Novacyt trades under the code ALNOV on the Euronext Paris in France, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Novacyt (ALNOV) trades on the Euronext Paris in France. It last closed at EUR 0.453 on 27 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 285 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 6.2% and over the last three months it rose 0.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.5% | ||
| From 52-week high | -49.8% | ||
| Momentum | 78 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 0.7% | ||
| 6-month return | 24.3% | ||
| 12-month return, skipping the last month | 5.0% | ||
| Stability (higher is calmer) | 16 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 93.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -57.3% | ||
| Liquidity | 66 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.14M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.6% |
|---|---|
| 1 month | −10.7% |
| 3 months | +0.7% |
| 6 months | +24.3% |
| 1 year | −6.2% |
| 3 years | −5.6% |
| 5 years | −84.7% |
Signals
| 50-day / 200-day average | 0.489 / 0.446 |
|---|---|
| Golden / death cross (60 days) | Golden, 50 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.020 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.